Curtis Layton

Protillion Biosciences, Inc. is a company based in Burlingame, CA that was founded in 2019 by Will Greenleaf, David R. Walt, and Curtis Layton. The company specializes in commercializing disruptive technology for therapeutic antibody and binder discovery. The company's high throughput instrumentation can characterize the binding affinity on the order of 1 million antibody variants in a 2-day automated run, enabling the identification of better antibody candidates on an exponentially faster timeline compared to current state-of-the-art antibody discovery and optimization techniques that may take months of laborious laboratory procedures executed by highly-skilled practitioners. Curtis Layton has been the CEO since 2019.